Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept versus bevacizumab for treatment of CRVO with macular edema
TCTR20191205008Terminated
- Sponsor
- Faculty of Medicine, Khon Kaen University
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of aflibercept and bevacizumab in central retinal vein occlusion (CRVO) and macular edema (2 arms), sponsored by Faculty of Medicine, Khon Kaen University. Started Dec 2019; status: terminated.
02
Drugs
afliberceptbevacizumab
03
Conditions
central retinal vein occlusion (CRVO)macular edema
Beyond the preview
Go deeper on TCTR20191205008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20191205008.